Ligand Pharmaceuticals Incorporated

LGND · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders2.4%

Institutions116.1%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$268.09M	$167.13M	$131.31M	$196.25M	$277.13M	$186.42M	$120.28M	$251.45M	$30.35M	$27.05M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$32.70M	$33.00M	$33.70M	$34.20M	$47.17M	$23.44M	$16.86M	$6.34M	$5.37M	$5.57M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$41.00M	-$22.61M	$11.94M	$3.04M	$78.89M	$25.84M	$807.08M	$163.73M	$68.08M	$43.88M
Operating income as a percentage of revenue.	15.3%	-13.5%	9.1%	1.5%	28.5%	13.9%	671.0%	65.1%	224.3%	162.2%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$124.45M	-$4.03M	$52.15M	-$33.36M	$57.14M	-$2.98M	$629.30M	$143.32M	$12.56M	-$1.64M
Net income divided by the number of shares outstanding — profit attributable to each share.	$6.00	$0.00	$3.00	$-1.00	$3.44	$-0.18	$33.00	$6.00	$0.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$6.00	$0.00	$2.00	$-1.00	$3.31	$-0.18	$31.00	$5.00	$0.00	$0.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$174.93M	$72.31M	$22.95M	$45.01M	$19.52M	$47.62M	$71.54M	$117.16M	$20.62M	$18.75M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.56B	$941.77M	$787.22M	$762.67M	$1.30B	$1.36B	$1.49B	$1.26B	$671.02M	$601.59M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	$0	$76.69M	–	–	$0	$26.43M	$224.53M	$212.91M
Everything the company owes — debt, unpaid bills, and other obligations.	$543.42M	$111.33M	$86.30M	$165.18M	$476.43M	$652.76M	$727.68M	$699.89M	$252.37M	$230.73M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$1.02B	$830.44M	$700.91M	$597.49M	$821.16M	$709.52M	$767.23M	$560.91M	$399.79M	$341.29M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$49.36M	$97.05M	$49.58M	$137.85M	$78.80M	$54.59M	-$29.34M	$194.06M	$93.57M	$63.00M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$452000	$1.82M	$3.52M	$17.92M	$8.76M	$4.46M	$2.55M	$887000	$2.16M	$1.85M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$48.91M	$95.23M	$46.06M	$119.93M	$70.04M	$50.13M	-$31.89M	$193.17M	$91.41M	$61.15M

	You	Peer avg
P/E	29.4	42.7
Revenue Growth	+33.7%	+632.7%
ROE	22.0%	119.4%

Ligand Pharmaceuticals Incorporated

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison